作者
Pauline Morigny,Marianne Houssier,Aline Mairal,Claire Ghilain,Etienne Mouisel,Fadila Benhamed,Bernard Masri,Emeline Recazens,Pierre-Damien Denechaud,Geneviève Tavernier,Sylvie Caspar‐Bauguil,Sam Virtue,Veronika Šrámková,Laurent Monbrun,Anne Mazars,Madjid Zanoun,Sandra Guilmeau,Valentin Barquissau,Diane Beuzelin,Sophie Bonnel,Marie Marquès,Boris Monge-Roffarello,Corinne Lefort,Barbara A. Fielding,Thierry Sulpice,Arne Astrup,Bernard Payrastre,Justine Bertrand‐Michel,Emmanuelle Meugnier,Lætitia Ligat,Frédéric Lopez,Hervé Guillou,Charlotte Ling,Cecilia Holm,Rémi Rabasa‐Lhoret,Wim H. M. Saris,Vladimír Štich,Peter Arner,Mikael Rydén,Cédric Moro,Nathalie Viguerie,Matthew J. Harms,Stefan Hallén,Antonio Vidal–Puig,Hubert Vidal,Catherine Postic,Dominique Langin
摘要
Impaired adipose tissue insulin signalling is a critical feature of insulin resistance. Here we identify a pathway linking the lipolytic enzyme hormone-sensitive lipase (HSL) to insulin action via the glucose-responsive transcription factor ChREBP and its target, the fatty acid elongase ELOVL6. Genetic inhibition of HSL in human adipocytes and mouse adipose tissue results in enhanced insulin sensitivity and induction of ELOVL6. ELOVL6 promotes an increase in phospholipid oleic acid, which modifies plasma membrane fluidity and enhances insulin signalling. HSL deficiency-mediated effects are suppressed by gene silencing of ChREBP and ELOVL6. Mechanistically, physical interaction between HSL, independent of lipase activity, and the isoform activated by glucose metabolism ChREBPα impairs ChREBPα translocation into the nucleus and induction of ChREBPβ, the isoform with high transcriptional activity that is strongly associated with whole-body insulin sensitivity. Targeting the HSL-ChREBP interaction may allow therapeutic strategies for the restoration of insulin sensitivity.